Jun 26 |
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
|
Jun 25 |
Ionis gains as anti-lipid therapy undergoes FDA priority review
|
Jun 25 |
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed
|
Jun 25 |
Ionis Pharmaceuticals (IONS) Soars 6.8%: Is Further Upside Left in the Stock?
|
Jun 19 |
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
|
Jun 18 |
Ionis announces expanded licensing agreement with Otsuka in Asia Pacific for investigational medicine donidalorsen in hereditary angioedema
|
Jun 17 |
Ionis to present at TD Cowen Genetic Medicines & RNA Summit
|
Jun 15 |
ALS therapy market seen increasing to nearly $1.3B by 2029
|
Jun 6 |
Ionis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
|
Jun 1 |
Shareholders Will Probably Not Have Any Issues With Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) CEO Compensation
|